Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)

NCT01520558 is registered in ClinicalTrials.gov with Coronado Biosciences, Inc. as lead sponsor.

NCT NCT01520558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01520558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Lead sponsor
Coronado Biosciences, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 31, 2012
Completion date
February 28, 2018
Enrollment
12 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia